Literature DB >> 20721632

Potential of magnetic resonance spectroscopy in assessing the effect of fatty acids on inflammatory bowel disease in an animal model.

Sonal Varma1, Michael N A Eskin, Ranjana Bird, Brion Dolenko, Jayadev Raju, Omkar B Ijare, Tedros Bezabeh.   

Abstract

People with inflammatory bowel disease (IBD) are at risk for developing colorectal cancer, and this risk increases at a rate of 1% per year after 8-10 years of having the disease. Saturated and omega-6 polyunsaturated fatty acids (PUFAs) have been implicated in its causation. Conversely, omega-3 PUFAs may have the potential to confer therapeutic benefit. Since proton magnetic resonance spectroscopy ((1)H MRS) combined with pattern recognition methods could be a valuable adjunct to histology, the objective of this study was to analyze the potential of (1)H MRS in assessing the effect of dietary fatty acids on colonic inflammation. Forty male Sprague-Dawley rats were administered one of the following dietary regimens for 2 weeks: low-fat corn oil (omega-6), high-fat corn oil (omega-6), high-fat flaxseed oil (omega-3) or high-fat beef tallow (saturated fatty acids). Half of the animals were fed 2% carrageenan to induce colonic inflammation similar to IBD. (1)H MRS and histology were performed on ex vivo colonic samples, and the (1)H MR spectra were analyzed using a statistical classification strategy (SCS). The histological and/or MRS studies revealed that different dietary fatty acids modulate colonic inflammation differently, with high-fat corn oil being the most inflammatory and high-fat flaxseed oil the least inflammatory. (1)H MRS is capable of identifying the biochemical changes in the colonic tissue as a result of inflammation, and when combined with SCS, this technique accurately differentiated the inflamed colonic mucosa based on the severity of the inflammation. This indicates that MRS could serve as a valuable adjunct to histology in accurately assessing colonic inflammation. Our data also suggest that both the type and the amount of fatty acids in the diet are critical in modulating IBD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20721632     DOI: 10.1007/s11745-010-3455-7

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  46 in total

Review 1.  Omega-3 fatty acids in inflammation and autoimmune diseases.

Authors:  Artemis P Simopoulos
Journal:  J Am Coll Nutr       Date:  2002-12       Impact factor: 3.169

2.  Chemical shift imaging of human colorectal tissue (ex vivo).

Authors:  D Ende; A Rutter; P Russell; C E Mountford
Journal:  NMR Biomed       Date:  1996-06       Impact factor: 4.044

3.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

4.  An analysis of creatine phosphokinase in the mucosa and the muscularis of the gastrointestinal tract.

Authors:  G M Graeber; P J Cafferty; R E Wolf; J W Harmon
Journal:  J Surg Res       Date:  1984-11       Impact factor: 2.192

5.  Analysis of plasma lipids by NMR spectroscopy: application to modifications induced by malignant tumors.

Authors:  M Kriat; J Vion-Dury; S Confort-Gouny; R Favre; P Viout; M Sciaky; H Sari; P J Cozzone
Journal:  J Lipid Res       Date:  1993-06       Impact factor: 5.922

6.  Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology.

Authors:  Jacob T Bjerrum; Ole H Nielsen; Fuhua Hao; Huiru Tang; Jeremy K Nicholson; Yulan Wang; Jørgen Olsen
Journal:  J Proteome Res       Date:  2010-02-05       Impact factor: 4.466

7.  Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial.

Authors:  Tadao Bamba; Takashi Shimoyama; Masaya Sasaki; Tomoyuki Tsujikawa; Yoshihiro Fukuda; Kazutaka Koganei; Toshifumi Hibi; Yasushi Iwao; Akihiro Munakata; Shinsaku Fukuda; Takayuki Matsumoto; Nobuhide Oshitani; Nobuo Hiwatashi; Tatsuo Oriuchi; Tetsuji Kitahora; Toshinori Utsunomiya; Yasushi Saitoh; Yasuo Suzuki; Mitsuyoshi Nakajima
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-02       Impact factor: 2.566

8.  Statistical total correlation spectroscopy editing of 1H NMR spectra of biofluids: application to drug metabolite profile identification and enhanced information recovery.

Authors:  Caroline J Sands; Muireann Coen; Anthony D Maher; Timothy M D Ebbels; Elaine Holmes; John C Lindon; Jeremy K Nicholson
Journal:  Anal Chem       Date:  2009-08-01       Impact factor: 6.986

9.  Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan.

Authors:  R Shoda; K Matsueda; S Yamato; N Umeda
Journal:  Am J Clin Nutr       Date:  1996-05       Impact factor: 7.045

10.  NMR lipid profiles of cells, tissues, and body fluids: proton NMR analysis of human erythrocyte lipids.

Authors:  R K Adosraku; G T Choi; V Constantinou-Kokotos; M M Anderson; W A Gibbons
Journal:  J Lipid Res       Date:  1994-11       Impact factor: 5.922

View more
  2 in total

1.  Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases.

Authors:  Tomasz Dawiskiba; Stanisław Deja; Agata Mulak; Adam Ząbek; Ewa Jawień; Dorota Pawełka; Mirosław Banasik; Agnieszka Mastalerz-Migas; Waldemar Balcerzak; Krzysztof Kaliszewski; Jan Skóra; Piotr Barć; Krzysztof Korta; Kornel Pormańczuk; Przemyslaw Szyber; Adam Litarski; Piotr Młynarz
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

2.  Eosinophil-mediated signalling attenuates inflammatory responses in experimental colitis.

Authors:  Joanne C Masterson; Eóin N McNamee; Sophie A Fillon; Lindsay Hosford; Rachel Harris; Shahan D Fernando; Paul Jedlicka; Ryo Iwamoto; Elizabeth Jacobsen; Cheryl Protheroe; Holger K Eltzschig; Sean P Colgan; Makoto Arita; James J Lee; Glenn T Furuta
Journal:  Gut       Date:  2014-09-10       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.